This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PharmaPoint: Multiple Sclerosis - Current And Future Players

NEW YORK, April 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Multiple Sclerosis - Current and Future Players http://www.reportlinker.com/p01158410/PharmaPoint-Multiple-Sclerosis---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Multiple Sclerosis - Current and Future Players

SummaryGlobalData has released its pharma report, "PharmaPoint: Multiple Sclerosis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Multiple Sclerosis Market. The report identifies and analyses the key companies shaping and driving the global Multiple Sclerosis market. The report provides insight into the competitive Multiple Sclerosis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope- Investigation of current and future market competition for Multiple Sclerosis- Competitor assessment- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.- Strategic assessment of the Multiple Sclerosis sector through market impact analysis, future market scenario and company analysis

Reasons to buy- Gain a high level view of the trends shaping and driving the Multiple Sclerosis Market- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.- Create an effective counter-strategy to gain a competitive advantage against those currently in the market- What's the next big thing in the global Multiple Sclerosis market landscape? Identify, understand and capitalize

Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 72 Introduction 82.1 Catalyst 82.2 Related Reports 93 Market Outlook 113.1 Global Markets 113.1.1 Forecast 113.1.2 Drivers and Barriers – Global Issues 134 Current and Future Players 174.1 Overview 174.2 Trends in Corporate Strategy 194.3 Company Profiles 214.3.1 Biogen Idec 214.3.2 Teva Pharmaceutical Industries 244.3.3 Merck Serono (EMD Serono) 274.3.4 Sanofi 304.3.5 Bayer HealthCare Pharmaceuticals 334.3.6 Novartis International 354.3.7 Hoffmann-La Roche 384.3.8 GlaxoSmithKline 405 Appendix 425.1 Bibliography 425.2 Abbreviations 425.3 Methodology 435.4 Forecasting Methodology 435.4.1 Diagnosed MS patients 435.4.2 Percent Drug-Treated Patients 445.4.3 Drugs Included in Each Therapeutic Class 445.4.4 Launch and Patent Expiry Dates 455.4.5 General Pricing Assumptions 465.4.6 Individual Drug Assumptions 475.4.7 Generic Erosion 505.4.8 Pricing of Pipeline agents 515.5 Physicians and Specialists Included in This Report 525.6 Primary Research – Prescriber Survey 535.7 About the Authors 535.7.1 Analysts 535.7.2 Global Head of Healthcare 545.8 About GlobalData 555.9 Contact Us 555.10 Disclaimer 55

List of TablesTable 1: Global Sales Forecasts ($m) for Multiple Sclerosis, 2012–2022 12Table 2: Global Multiple Sclerosis Market – Drivers and Barriers, 2012 13Table 3: Key Companies in the Multiple Sclerosis Market, 2012 18Table 4: Biogen's Multiple Sclerosis Portfolio Assessment, 2012 22Table 5: Biogen SWOT Analysis, 2012 23Table 6: Teva's Multiple Sclerosis Portfolio Assessment, 2012 25Table 7: Teva SWOT Analysis, 2012 26Table 8: Merck's Multiple Sclerosis Portfolio Assessment, 2012 28Table 9: Merck SWOT Analysis, 2012 29Table 10: Sanofi's Multiple Sclerosis Portfolio Assessment, 2012 31Table 11: Sanofi SWOT Analysis, 2012 32Table 12: Bayer's Multiple Sclerosis Portfolio Assessment, 2012 34Table 13: Bayer SWOT Analysis, 2012 34Table 14: Novartis' Multiple Sclerosis Portfolio Assessment, 2012 36Table 15: Novartis SWOT Analysis, 2012 37Table 16: Roche's Multiple Sclerosis Portfolio Assessment, 2012 39Table 17: Roche SWOT Analysis, 2012 39Table 18: GlaxoSmithKiline's Multiple Sclerosis Portfolio Assessment, 2012 41Table 19: GlaxoSmithKline SWOT Analysis, 2012 41Table 20: Key Launch Dates 45Table 21: Key Patent Expiries 45Table 22: Physicians Surveyed, By Country 53

List of FiguresFigure 1: Global Market Sales for Multiple Sclerosis by Region, 2012–2022 13Figure 2: Company Portfolio Gap Analysis in Multiple Sclerosis, 2012–2022 20

Companies MentionedBiogen IdecTeva Pharmaceutical IndustriesMerck Serono (EMD Serono)SanofiBayer HealthCare PharmaceuticalsNovartis InternationalHoffmann-La RocheGlaxoSmithKline

To order this report: Pathology Industry: PharmaPoint: Multiple Sclerosis - Current and Future Players

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs